Skip to main content

Table 1 Responses collected from the HCPs survey

From: The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys

Category

n (%)

Group of IMD patients followed at the centre

 

 Adult

8/73 (11)

 Paediatric

18/73 (24.7)

 Both

47/73 (64.4)

Paediatric patients infected with SARS-CoV-2 (confirmed by testing) in the centre

 

 Yes

5/73 (6.9)

 No

62/73 (84.9)

 Do not know

6/73 (8.2)

 Total number of paediatric reported cases

13

Symptoms of paediatric patients positive for COVID-19

 

At diagnosis

 

 Asymptomatic

1/13 (8)

 Mild

12/13 (92)

 Severe

0/13 (0)

 Do not know

0/13 (0)

During the infection

 

 Asymptomatic

1/13 (8)

 Mild

12/13 (92)

 Severe with need of hospitalisation

0/13 (0)

 Required intensive care

0/13 (0)

Adult patients infected with SARS-CoV-2 (confirmed by testing) in the centre

 

 Yes

7/73 (9.6)

 No

54/73 (74)

 Do not know

12/73 (16.4)

 Total number of adult reported cases

11

Symptoms of adult patients positive for COVID-19

 

At diagnosis

 

 Asymptomatic

0/11 (0)

 Mild

10/11 (91)

 Severe

1/11 (9)

 Do not know

0/11 (0)

During the infection

 

 Asymptomatic

0/11 (0)

 Mild

9/11 (82)

 Severe with need of hospitalisation

2/11 (18)

 Required intensive care

0/11 (0)

Casualties due to COVID-19 among IMD patients

 

 Yes

0/73 (0)

 No

64/73 (87.7)

 Do not know

9/73 (12.3)

Change needed in the management of IMD patients

 

 Yes

66/73 (90.4)

 No

7/73 (9.6)

Change needed in the therapy regime of IMD patients with no COVID-19*

 

 Yes, the frequency of therapy has been reduced

19/73 (26)

 Yes, the therapy has been stopped

3/73 (4.1)

 Yes, the frequency of rehabilitation has been reduced

12/73 (16.4)

 Yes, rehabilitation has been stopped

15/73 (20.6)

 Only for some specific cases

14/73 (19.2)

 No

26/73 (35.6)

Changes in therapeutic regimes unified at national or regional level

 

 Yes

25/45 (55.6)

 No

20/45 (44.4)

Proportion of missed outpatient visit for IMD at the centre

 

 0–25%

5/73 (6.9)

 25–50%

3/73 (4.1)

 50–75%

20/73 (27.4)

 75–100%

40/73 (54.8)

 Not applicable

5/73 (6.9)

Outpatient face-to-face visits replaced by video conference/telephone interaction

 

 Yes

66/73 (90.4)

 No

4/73 (5.5)

 Not applicable

3/73 (4.1)

Patients stopped treatment by their own decision

 

 Yes

10/73 (13.7)

 No

57/73 (78.1)

 Do not know

6/73 (8.2)

Disease categories expected to be at major risk in relation to COVID-19*

 

 AOA

42/73 (57.5)

 PM-MD

41/73 (56.2)

 C-FAO

33/73 (45.2)

 LSD

38/73 (52)

 PD

14/73 (19.2)

 CDG

18/73 (24.7)

 NOMS

9/73 (12.3)

Awareness of good-quality informative material about COVID-19 and IMD

 

 Yes

26/73 (35.6)

 No

33/73 (45.2)

 Do not know

14/73 (19.2)

Centre produced informative material about COVID-19 and IMD

 

 Yes

27/73 (37)

 No

42/73 (57.5)

 Do not know

4/73 (5.5)

Centre offering special informative/psychological support to IMD patients during the pandemic

 

 Yes

43/73 (58.9)

 No

24/73 (32.9)

 Do not know

6/73 (8.2)

PO helping HCP in providing special support during the pandemic

 

 Yes

42/73 (57.5)

 No

21/73 (28.8)

 Do not know

10/73 (13.7)

Active COVID-19 helpline for IMD patients in the centre

 

 Yes

38/73 (52.1)

 No

32/73 (43.8)

 Do not know

3/73 (4.1)

Patients prone to metabolic crises have the same open access to hospital as before the COVID-19 outbreak

 

 Yes

49/73 (67.1)

 No

18/73 (24.7)

 Do not know

6/73 (8.2)

  1. *More than one answer possible
  2. AOA, amino and organic acids-related disorders; PM-MD, disorder of pyruvate metabolism, Krebs cycle defects, mitochondrial oxidative phosphorylation disorders, disorders of thiamine transport and metabolism; C-FAO, carbohydrate, fatty acid oxidation and ketone bodies disorders; LSD, lysosomal storage disorders; PD, peroxisomal disorders; CDG, congenital disorders of glycosylation and disorders of intracellular trafficking; NOMS, disorders of neuromodulators and other small molecules